Furthermore, seven bioactive compounds (isorhamnetin, kaempferol, 8-Isopentenyl-kaempferol, norartocarpetin, wighteone, quercetin, and beta-sitosterol) were found in the BSJPJDD, among which quercetin and wighteone targeted IL-1A regulating MEKK1, P38, MEK3, TAK1, and isorhamnetin, and wighteone and quercetin targeted EGF regulating JNK and ERK in the MAPK pathway (Figure 3E), indicating that these compounds of BSJPJDD might activate multiple pathways to inhibit tumor progression, increase survival, and improve life quality in PCRC patients. The gene discussed is MAPK8; the disease is neoplasm.